Brief: FDA Clears Brainsway Deep Tms™ System For Decreasing Anxiety Symptoms In Depressed Patients
18/08/2021 12:43
Aug 18 (Reuters) - Brainsway Ltd BWAY.TA :
* FDA CLEARS BRAINSWAY DEEP TMS™ SYSTEM FOR DECREASING
ANXIETY
SYMPTOMS IN DEPRESSED PATIENTS
Source text for Eikon: ID:nGNXP9HxY
Further company coverage: BWAY.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)